Success Metrics

Clinical Success Rate
90.9%

Based on 20 completed trials

Completion Rate
91%(20/22)
Active Trials
1(4%)
Results Posted
40%(8 trials)
Terminated
2(7%)

Phase Distribution

Ph phase_2
10
37%
Ph phase_4
1
4%
Ph phase_3
5
19%
Ph early_phase_1
1
4%
Ph phase_1
10
37%

Phase Distribution

11

Early Stage

10

Mid Stage

6

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
1(3.7%)
Phase 1Safety & dosage
10(37.0%)
Phase 2Efficacy & side effects
10(37.0%)
Phase 3Large-scale testing
5(18.5%)
Phase 4Post-market surveillance
1(3.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.0%

20 of 23 finished

Non-Completion Rate

13.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

27

all time

Status Distribution
Active(1)
Completed(20)
Terminated(3)
Other(3)

Detailed Status

Completed20
unknown3
Terminated2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
1
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.7%)
Phase 110 (37.0%)
Phase 210 (37.0%)
Phase 35 (18.5%)
Phase 41 (3.7%)

Trials by Status

unknown311%
withdrawn14%
completed2074%
recruiting14%
terminated27%

Recent Activity

1 active trials
Showing 5 of 27
recruitingphase_1

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

NCT05296304
completedphase_1

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

NCT04664829
completedphase_1

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658
completedphase_3

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

NCT01578499
terminatedphase_2

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia

NCT00615784
View all 27 trials

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT05296304Phase 1

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

Recruiting
NCT04664829Phase 1

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Completed
NCT03323658Phase 1

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

Completed
NCT01578499Phase 3

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Completed
NCT00615784Phase 2

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia

Terminated
NCT00411632Phase 2

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT01007448Phase 4

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

Completed
NCT00425477Phase 2

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed
NCT00056056Phase 3

Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides

Terminated
NCT00316030Phase 1

Study of Bexarotene in Patients With Acute Myeloid Leukemia

Completed
NCT01782742Phase 2

Bexarotene Amyloid Treatment for Alzheimer's Disease

Completed
NCT02061878Phase 1

A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects

Completed
NCT00660231Phase 2

Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma

Completed
NCT01001143Phase 1

Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)

Completed
NCT00718770Early Phase 1

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

Completed
NCT00514293Phase 2

Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Unknown
NCT00030589Phase 2

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

Unknown
NCT00003752Phase 2

Bexarotene in Treating Patients With Metastatic Breast Cancer

Completed
NCT00050973Phase 3

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Completed
NCT00030849Phase 2

Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
27